Delivery Order SPE2DB22D3501-SPE2DB25FXL23
- Not listed
- The Defense Logistics Agency awarded a $1,306.78 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 2, 2025, and performance to be executed at the vendor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $3,109.75 to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price delivery order is set to be completed by August 7, 2025, with performance occurring at the vendor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,906.45. The award, made on August 8, 2025, is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025. This non-competitive set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete...
- The Defense Logistics Agency awarded a $14,404.96 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound (semaglutide) 15 mg/0.5 mL pen injectors with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under the company's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections, with a ceiling value of $2,669.03 and an ultimate completion date of September 18, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,037.49 delivery order on September 2, 2025, for Zepbound 10 mg/0.5 ml pen (semaglutide injection), with performance completion scheduled for September 3, 2025. The contract is structured as a firm fixed price delivery order under a non-competitive set-aside designation, with performance to be executed at the contractor's Conshohocken, Pennsylvania location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $13,120.39 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $30,324.00 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on September 16, 2025, with an ultimate completion date of September 17, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, and the place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a child contract issued under a larger...
- The Defense Logistics Agency awarded a $1,143.87 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on September 5, 2025, with completion targeted for September 8, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime IDC running through December 2026. The product will be performed at the...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXL23Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,906.45 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors on September 19, 2025, with completion anticipated by September 22, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor serving the federal healthcare system, delivers a broad portfolio of medications and medical supplies to support military and veteran healthcare needs through the Defense Logistics Agency's supply chain. This delivery order for Zepbound reflects the company's role as a critical vendor for specialized pharmaceutical commodities, consistent with its track record of fulfilling federal medical procurement requirements across therapeutic domains including endocrinology, neurology, pain management, and infectious disease. The order supports the Defense Health Agency and other government healthcare systems requiring diabetes medications and weight management therapeutics.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/19/25 |